Published in Hepatitis Weekly, January 17th, 2000
"Current protocols for prophylaxis against allograft reinfection after liver transplantation for chronic HBV infection include the administration of large doses of HBIG, with considerable associated costs. Monotherapeutic prophylaxis with lamivudine has been complicated by the development of resistant strains of HBV," wrote E. M. Yoshida, of the Vancouver Hospital and Health Science Center, and colleagues.
The researchers administered a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.